Hormone therapy safe for early menopause, research confirms—timing is key

For decades, doctors and patients have lived in a fog of uncertainty about hormone therapy during menopause. The treatment relieves hot flashes, night sweats, and sleep disruption—symptoms that can be genuinely disabling. But is it safe? The answer, it turns out, depends almost entirely on when a woman starts taking it.

Menopause arrives when a woman has gone twelve consecutive months without a menstrual period, typically between ages forty-five and fifty-five. The years leading up to it, called perimenopause, can stretch on for several years, marked by wild swings in estrogen and progesterone. These hormonal shifts do more than cause the hot flashes everyone knows about. They reshape the cardiovascular system in ways most women never learn about. Estrogen, it turns out, is a protector of the heart and blood vessels. It keeps arteries flexible, helps produce nitric oxide—a molecule that allows vessels to relax and maintain healthy blood flow—and influences how the body processes cholesterol. When estrogen plummets, blood vessels stiffen, cholesterol rises, inflammation increases, and fat deposits shift in ways that promote plaque buildup inside arteries. The result is a sharp rise in cardiovascular disease risk, the leading cause of death among women worldwide.

Hormone therapy—either estrogen alone or estrogen combined with progestin, a synthetic form of progesterone—restores those falling hormone levels and quiets menopausal symptoms. Doctors prescribed it widely in the 1970s, marketing it almost as a fountain of youth, a way to prevent heart attacks, strokes, and other age-related diseases. Then came a seismic shift. In the early 2000s, the Women's Health Initiative, one of the largest clinical trials ever conducted on hormone therapy, found that women taking it faced increased risks of stroke and breast cancer. The medical establishment reversed course almost overnight. Guidelines shifted. Prescriptions dried up. The treatment that had been hailed as preventive medicine was suddenly seen as dangerous.

But the story did not end there. Researchers who dug deeper into the Women's Health Initiative data, combined with findings from subsequent studies, began to see a pattern. The risks and benefits of hormone therapy, they realized, were not uniform across all women. They depended on timing—specifically, on how soon after menopause began a woman started the treatment. This became known as the timing hypothesis: hormone therapy appears to lower the risk of heart disease in women under sixty who start it within ten years of menopause onset and who are otherwise healthy. Women who begin much later—after sixty or more than a decade past menopause—may face increased cardiovascular risks instead.

A 2019 analysis of thirty-one clinical trials supported this theory. Women under sixty who used hormone therapy tended to live longer and were less likely to die from heart disease. The same analysis did identify increased risks of blood clots and stroke, risks that were present even in younger women and that climbed with age. But the method of delivery mattered. Estrogen patches worn on the skin carried a lower blood clot risk than pills. The reason is a phenomenon called first-pass metabolism: when hormone therapy is swallowed, the liver processes it before it enters the bloodstream, and the liver produces clotting factors. Patches bypass the liver entirely, delivering estrogen directly into the bloodstream, and do not trigger this clotting response. Women taking oral hormone therapy also tended to have lower cholesterol levels, an effect that persisted over years.

The medical consensus has shifted again, but this time toward nuance rather than certainty. Hormone therapy is not recommended for women with existing heart disease, a history of blood clots, prior stroke, gallbladder disease, or certain cancers. For healthy younger women within ten years of menopause onset, however, it is now considered safe from a cardiovascular standpoint and may even provide benefit. The era of blanket recommendations—for or against—has ended. Instead, treatment decisions should be tailored to each woman's age, how long ago menopause began, her overall health, and her preferences. The fog has not entirely lifted, but the path forward is clearer now: a conversation between patient and doctor, grounded in her specific circumstances, not in fear or outdated guidelines.